Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 52-Week Low Following Analyst Downgrade

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday after StockNews.com downgraded the stock from a buy rating to a hold rating. The company traded as low as $23.34 and last traded at $23.46, with a volume of 45380 shares trading hands. The stock had […]

Related Keywords

United States ,Piper Sandler ,Tami Tillotson Martin ,Stephens Investment Management Group ,Blackrock Inc ,News Ratings For Supernus Pharmaceuticals Daily ,Securities Exchange Commission ,Supernus Pharmaceuticals Stock Down ,Supernus Pharmaceuticals ,Dimensional Fund Advisors ,Macquarie Group Ltd ,Vanguard Group Inc ,Institutional Investors Weigh In On Supernus Pharmaceuticals ,Nasdaq ,Supernus Pharmaceuticals Inc ,Get Free Report ,Tillotson Martin ,Exchange Commission ,Fund Advisors ,Investment Management Group ,Pharmaceuticals Stock Down ,Supernus Pharmaceuticals Daily ,Nasdaq Supn ,Supn ,Medical ,86845910 ,Stocks ,Technicals ,